Media Pack
News

Current Edition

Volume 16 Issue 1
 
Regional News

Merck’s reported $11B Acceleron buy could help it diversify beyond Keytruda, but antitrust hurdles loom

Merck has emerged as a finalist to acquire Acceleron for around $11 billion. The deal dovetails with the Big Pharma company’s plan to diversify beyond its immuno-onco...
29 September 2021 Regional News Acceleron | immuno-oncology
Continue Reading →
Regional News

ESMO: Bristol Myers’ Opdivo-Yervoy, Pfizer-Merck KGaA’s Bavencio hit walls in head and neck cancer

Suffering two separate clinical trial blows, Bristol Myers Squibb and a collaboration between Merck KGaA and Pfizer learned the hard way that head and neck cancer is ...
22 September 2021 Regional News Bavencio | Bristol Myers
Continue Reading →
Regional News

Merck women’s health spinoff Organon debuts first awareness campaign, taking on unplanned pregnancy

When Merck's women’s health spinoff Organon launched in June, it promised to listen to—and amplify—women’s voices on overlooked health concerns. Now, the company is ...
22 September 2021 Regional News Merck | Organon
Continue Reading →
Regional News

Organon shares jump as Merck’s new women’s health spinoff posts strong start for biosims, infertility drugs

It’s been a mere two months since Merck’s women’s health spinoff Organon set off to chart its own path as an independent company. That hasn’t been an easy feat amid a...
18 August 2021 Regional News biosims | infertility drugs
Continue Reading →
Regional News

Merck’s Welireg scores FDA nod in cancers spurred by rare disease—and its label is broader than expected

Merck’s $1.1 billion bet on Peloton Therapeutics is starting to pay off. Belzutifan, one of the most lucrative assets Merck picked up through its 2019 Peloton buy, s...
18 August 2021 Regional News Belzutifan | central nervous system
Continue Reading →
Regional News

Merck’s Keytruda scores first-in-class nod in early triple-negative breast cancer despite FDA’s prior reluctance

The FDA had reservations about Merck & Co.’s proposed use of Keytruda around surgery for patients with early triple-negative breast cancer. But less than three mo...
4 August 2021 Regional News breast cancer | clinical trial
Continue Reading →
 
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2024, All Rights Reserved – Powered by Teksyte